The approval has been granted to Vuity (formerly AGN-190584), a once-daily eyedrop formulation of muscarinic cholinergic agonist pilocarpine developed by AbbVie's Allergen unit that is now an ...

Now, there could be another alternative, in the form of eye drops administered daily, according to AbbVie's Allergan subsidiary, which reported new phase 3 data for its pilocarpine formulation ...

The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, Sichuan, P. R. China Center for ...